Uppsala, Sweden, March 12, 2020. Biovica, active in cancer diagnostics, today announced that results from a study by researchers at Lund University have been published in the well renowned journal Scientific Reports, a journal from Nature. The results support that the blood test DiviTum can be used as a prognostic tool for evaluating treatment outcomes in metastatic breast cancer.
The study evaluated thymidine kinase activity in 142 women with newly diagnosed metastatic breast cancer as a tool for first-line prognosis and monitoring. Activity was measured by Biovica’s DiviTum test at diagnosis and after 1, 3 and 6 months of treatment. The patients in the study received standard therapy such as hormonal therapy, chemotherapy and HER2-targeted therapy.
The results show that measurement of levels of thymidine kinase activity with DiviTum predicts patient outcomes and is clinically valuable in improving prognosis and monitoring of treatment of newly diagnosed metastatic breast cancer patients. Decreasing levels of thymidine kinase activity correlate with prolonged time to disease progression and survival.
“Our study shows that DiviTum can provide additional information on prognosis and therapy efficacy in women with metastatic breast cancer treated with today’s standard therapies. For me as an oncologist, this means that I can get complementary information on the development of the disease that can influence treatment decisions with the goal of better outcome and quality of life for the patient. We are interested in continuing to evaluate DiviTum for women with metastatic breast cancer in larger studies,” said Anna-Maria Larsson, MD, oncologist and lead investigator in the study at Skåne University Hospital in Lund and Lund University.
“The study is a strong confirmation of previous studies in metastatic breast cancer. DiviTum has been used in seven published studies in more than 1,000 breast cancer patients. The study in Lund shows that DiviTum can be used as an independent prognostic tool in this indication. The goal for Biovica is for DiviTum to become a standard tool for evaluating treatment efficacy in patients with metastatic breast cancer,” said Anders Rylander, CEO of Biovica.
Link to the publication: https://www.nature.com/articles/s41598-020-61416-1
For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.
Biovica – Best Treatment from Day One
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica’s vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica’s shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company’s Certified Adviser, email@example.com, +46 8 528 00 399. For more information please visit: www.biovica.com.